Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Investment of the day
    • 1mg raises Rs 100...

    1mg raises Rs 100 crore in series C funding by HBM Healthcare

    Written by Ruby Khatun Khatun Published On 28 July 2017 4:00 AM  |  Updated On 28 July 2017 4:00 AM

    Bengaluru: 1mg Technologies Pvt Ltd, India’s largest digital health platform which operates mobile app “1mg” on Android/ iOS and the web platform www.1mg.com, announced that it has closed a financing round of ~$15 million (about Rs 100 crore), led by HBM Healthcare Investments with participation from other existing investors Maverick, Sequoia India, Omidyar & Kae Capital.


    HBM had made its first investment in 1mg last year in May 2016, as a part of a top-up round following the Series B financing that was led by Maverick Capital Ventures.


    HBM is among the global leaders in healthcare-focused investing with around USD 1.5 billion under management. HBM focuses on development stage, growth and buy-out financings of private companies, as well as investments in public companies.


    Dr Andreas Wicki, CEO of HBM Healthcare Investments said “1mg was HBM's first investment in a digital health platform in India and we are very encouraged about the prospects of the company given the tremendous progress across all dimensions over the last year. 1mg has cemented its clear market leadership in the Indian digital health space. HBM decided to lead the current round and double down on its investment in 1mg, pre-empting any need for the company to seek external capital and keeping the focus on continued growth. As a specialised healthcare investor, we have been monitoring the interesting impact that technology is having in the space of healthcare delivery. In our view 1mg has created a unique platform in one of the fastest growing markets in the world, and this platform can be the foundation of India’s leading healthcare services business in the years ahead. All companies in the healthcare domain are looking for innovative platforms to partner with to connect better with their consumers – very few platforms have managed to achieve the consumer engagement at scale like 1mg has done.”


    Existing investors including Maverick Capital Ventures, Sequoia India, Omidyar Network & Kae Capital also participated in the financing round. Matthew Kinsella, Partner at Maverick commented “Digital health is coming of age globally, and Maverick is extremely excited by this space with over 30 investments. 1mg is clearly leading the charge in India, and Maverick along with the rest of the internal investors are keen to ensure the company has sufficient firepower to consolidate its leadership in this large market. This opportunity is a rare combination of being part of a venture that has leadership in the right market, at the right time, and with the right team to build a solid business.”


    Prashant Tandon, CEO & co-founder 1mg said, “I am really glad that our investors have chosen to re-affirm their faith in the potential of 1mg. We are truly excited by the opportunity to make a meaningful impact on how healthcare is delivered in India, and we believe that we are on the right path. Making healthcare transparent, understandable, accessible and affordable for consumers is a very important need of the ecosystem and also a huge opportunity to build a strong and sustainable business. Healthcare in India is going through profound changes, and we aspire to be the trusted partner of consumers as they navigate this space.”


    The company has previously raised funding from Maverick Capital Ventures, HBM Healthcare Investments, Sequoia Capital India, Omidyar Network, Kae Capital etc.

    1mg1mg Technologies Pvt LtdAndroid/ iOSdigital healthDr Andreas  WickifundFund raisefund raisingfundingHBM HealthcareHBM Healthcare InvestmentsInvestmentInvestorsMaverickmobile appOmidyar & Kae CapitalPrashant TandonRaisesSequoia Indiaseries C fundingwww.1mg.com
    Source : PRESS RELEASE

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok